Ignite Creation Date:
2024-05-06 @ 2:49 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04431349
Status:
COMPLETED
Last Update Posted:
2020-06-16
First Post:
2020-05-07
Brief Title:
Comparison of CABG Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel
Sponsor:
Ajou University School of Medicine
Organization:
Ajou University School of Medicine
Study Overview
Official Title:
Comparison of Coronary Artery Bypass Graft Surgery Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel
Status:
COMPLETED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CABG
Brief Summary:
In patients with coronary artery disease dual antiplatelet therapy acetylsalicylic acid and a P2Y12-receptor antagonist is a commonly used method because of its excellent antithrombotic effect In particular in patients with acute myocardial infarction who receive coronary angiography as an emergency the dual antiplatelet is used immediately before the test to prevent and test further clot formation regardless of whether or not the patient had previously taken dual antiplatelet
Ticagrelor a direct-acting and reversible ADP receptor antagonist was introduced in Denmark in 2013 and is now the most commonly used ADP receptor antagonist in the treatment of ACS Compared to its predecessor clopidogrel the pharmacokinetic profil of ticagrelor is more predictable demonstrating a faster onset of action and a more consistent platelet inhibition However because of the excellent antithrombotic effect and increased bleeding potential it is recommended that major bleeding such as OPCAB or CABG surgery be expected with a high probability and in case of fatal surgery the drug should be discontinued for 5 days
Most patients who receive emergency coronary heart surgery after undergoing coronary angiography as an emergency due to an acute myocardial infarction it take approximately 24-48 hours to undergo surgery after examination In fact there have been reports of large-scale cross-country studies that do not increase bleeding risk compared to 5 days until 3 days after ticagrelor is stopped Therefore this study aimed to retrospectively analyze the bleeding tendency by analyzing the records of patients using clopidogrel or ticagrelor in preoperative coronary angiography for patients undergoing emergency CABG surgery from 2016 to September 2019
Ticagrelor a direct-acting and reversible ADP receptor antagonist was introduced in Denmark in 2013 and is now the most commonly used ADP receptor antagonist in the treatment of ACS Compared to its predecessor clopidogrel the pharmacokinetic profil of ticagrelor is more predictable demonstrating a faster onset of action and a more consistent platelet inhibition However because of the excellent antithrombotic effect and increased bleeding potential it is recommended that major bleeding such as OPCAB or CABG surgery be expected with a high probability and in case of fatal surgery the drug should be discontinued for 5 days
Most patients who receive emergency coronary heart surgery after undergoing coronary angiography as an emergency due to an acute myocardial infarction it take approximately 24-48 hours to undergo surgery after examination In fact there have been reports of large-scale cross-country studies that do not increase bleeding risk compared to 5 days until 3 days after ticagrelor is stopped Therefore this study aimed to retrospectively analyze the bleeding tendency by analyzing the records of patients using clopidogrel or ticagrelor in preoperative coronary angiography for patients undergoing emergency CABG surgery from 2016 to September 2019
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None